Science News
Discover the news and inspiring materials from the world of biotechnology.
Mabion expert will conduct workshops on digital transformation in GMP
Digital transformation in GMP replaces manual paper workflows with connected technologies to boost compliance, data integrity, and efficiency. Amanda Jabłońska specializes in implementing quality systems and digital solutions.
Learn more
Breakthrough in the treatment of Huntington’s disease
New treatment for Huntington’s disease is nearing approval in the United States and the United Kingdom. This clinical momentum is driven by remarkable three-year results from multi-centre Phase I/II trials evaluating patients with early-manifest Huntington’s disease. In the high-dose treatment cohort, AMT-130 demonstrated a 75 percent slowing of clinical disease progression based on the Unified Huntington’s Disease Rating Scale.
Learn more
Jakub Knurek once again among the TOP 5 Future Leaders at the CPHI Pharma Awards
Jakub Knurek, a Marketing Specialist at Mabion S.A., has been named a finalist in the Future Leader category of the CPHI Pharma Awards 2026, to be awarded at CPHI Milan on 6 October. The award recognizes rising talents in pharma, biopharma, academia, or research settings, with at least five years of relevant experience and a maximum age of 35 by the ceremony date.
Learn more
Success of mRNA Cancer Vaccine
Developed jointly by Moderna and MSD intismeran autogene represents the first individualised mRNA-based cancer vaccine to demonstrate a statistically significant benefit in a Phase 3 randomised clinical trial.
Learn more
MabionCD20 development path in dialogue with the FDA
Mabion and Oddifact have submitted documentation to the FDA, including a request for a Type B Pre-IND meeting concerning the planned development of MabionCD20 in immune thrombocytopenia. The regulatory interaction is intended to address the preclinical program, CMC strategy and clinical development pathway, supporting define the requirements for potential progression toward clinical trials.
Learn more
Mabion receives the Responsible Entrepreneur Certificate
Mabion has been awarded the Responsible Entrepreneur Certificate in recognition of its commitment to environmental protection, sustainability and corporate social responsibility.
Learn more
New ranibizumab biosimilar enters the market
Ranibizumab is one example of a biologic drug that has achieved market success. Let’s trace the transformation of retinal disease treatment from the landmark 2006 approval of Lucentis to the current competitive era defined by more affordable biosimilar alternatives.
Learn more
Izenivetmab is available for veterinary use in the EU
Izenivetmab is a long-acting monoclonal antibody therapy made by Zoetis to treat joint pain from osteoarthritis in dogs. This medicine has received regulatory approvals in the European Union, the United Kingdom and Canada.
Learn more
Mabion and KriSan Biotech sign Agreement to strengthen next-generation ADC services
The Master Service Agreement between Mabion and KriSan Biotech was signed at the BIO Asia–Taiwan by Rongjin Lin, Chairman of KriSan Biotech Co., Ltd., and Gregor Kawaletz, CEO of Mabion, in the presence of representatives from the Ministry of Foreign Affairs of the Republic of Poland and the Ministry of Economic Affairs (Taiwan).
Learn more